MGRM vs. SMTI, LUNG, DRTS, ELMD, ZYXI, INGN, NYXH, RCEL, CATX, and PROF
Should you be buying Monogram Orthopaedics stock or one of its competitors? The main competitors of Monogram Orthopaedics include Sanara MedTech (SMTI), Pulmonx (LUNG), Alpha Tau Medical (DRTS), Electromed (ELMD), Zynex (ZYXI), Inogen (INGN), Nyxoah (NYXH), AVITA Medical (RCEL), Perspective Therapeutics (CATX), and Profound Medical (PROF). These companies are all part of the "medical equipment" industry.
Monogram Orthopaedics vs.
Monogram Orthopaedics (NASDAQ:MGRM) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, valuation, profitability and risk.
Monogram Orthopaedics has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.
Sanara MedTech received 17 more outperform votes than Monogram Orthopaedics when rated by MarketBeat users. However, 100.00% of users gave Monogram Orthopaedics an outperform vote while only 55.88% of users gave Sanara MedTech an outperform vote.
In the previous week, Monogram Orthopaedics' average media sentiment score of 1.00 beat Sanara MedTech's score of 0.50 indicating that Monogram Orthopaedics is being referred to more favorably in the media.
0.5% of Monogram Orthopaedics shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 28.1% of Monogram Orthopaedics shares are owned by company insiders. Comparatively, 54.1% of Sanara MedTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Monogram Orthopaedics currently has a consensus target price of $4.00, indicating a potential upside of 55.64%. Sanara MedTech has a consensus target price of $47.00, indicating a potential upside of 44.00%. Given Monogram Orthopaedics' stronger consensus rating and higher possible upside, equities analysts plainly believe Monogram Orthopaedics is more favorable than Sanara MedTech.
Sanara MedTech has higher revenue and earnings than Monogram Orthopaedics. Sanara MedTech is trading at a lower price-to-earnings ratio than Monogram Orthopaedics, indicating that it is currently the more affordable of the two stocks.
Monogram Orthopaedics has a net margin of 0.00% compared to Sanara MedTech's net margin of -10.71%. Sanara MedTech's return on equity of -19.86% beat Monogram Orthopaedics' return on equity.
Summary
Monogram Orthopaedics and Sanara MedTech tied by winning 9 of the 18 factors compared between the two stocks.
Get Monogram Orthopaedics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGRM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monogram Orthopaedics Competitors List
Related Companies and Tools
This page (NASDAQ:MGRM) was last updated on 1/21/2025 by MarketBeat.com Staff
Free MGRM Stock Alerts